Sanofi, GSK Start New Covid-19 Vaccine Study After Setback
February 22 2021 - 6:29AM
Dow Jones News
By Cecilia Butini
Sanofi SA said Monday that it has begun a new clinical trial for
the coronavirus vaccine it is developing with GlaxoSmithKline PLC
after a previous study failed to elicit sufficient immune response
to the virus in older adults.
The French pharmaceutical major said the new study, which is in
phase 2, will assess whether a refined antigen formulation is able
to achieve optimal immune response, including in older adults.
A previous phase 1-2 study had shown last December a lower
immune response in that age group, likely due to an insufficient
concentration of the antigen used in the shot, the company
said.
If the results from phase 2 are positive, the companies plan to
carry out a phase 3 trial in the second quarter of 2021, Sanofi
said. In case of positive results, a regulatory submission would
happen in the second half of 2021, making vaccines available in the
fourth quarter of the year in case of approval.
Sanofi added that it has also started development work against
new variants of the SARS-CoV-2 coronavirus.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
February 22, 2021 06:14 ET (11:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024